TRANXENE SD Drug Patent Profile

Which patents cover Tranxene Sd, and what generic alternatives are available?

Tranxene Sd is a drug marketed by Ajenat Pharms and is included in one NDA.

The generic ingredient in TRANXENE SD is clorazepate dipotassium. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the clorazepate dipotassium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tranxene Sd

A generic version of TRANXENE SD was approved as clorazepate dipotassium by AUROBINDO PHARMA on July 17^th, 1987.

Summary for TRANXENE SD

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	3
DailyMed Link:	TRANXENE SD at DailyMed

Recent Clinical Trials for TRANXENE SD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assistance Publique - Hôpitaux de Paris	Phase 3
Polish Lymphoma Research Group	Phase 4
Ranbaxy Laboratories Limited	N/A

See all TRANXENE SD clinical trials

US Patents and Regulatory Information for TRANXENE SD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ajenat Pharms	TRANXENE SD	clorazepate dipotassium	TABLET;ORAL	017105-005	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Ajenat Pharms	TRANXENE SD	clorazepate dipotassium	TABLET;ORAL	017105-004	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for TRANXENE SD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ajenat Pharms	TRANXENE SD	clorazepate dipotassium	TABLET;ORAL	017105-005	Approved Prior to Jan 1, 1982
Ajenat Pharms	TRANXENE SD	clorazepate dipotassium	TABLET;ORAL	017105-004	Approved Prior to Jan 1, 1982

International Patents for TRANXENE SD

See the table below for patents covering TRANXENE SD around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	958708	PROCESS FOR BENZODIAZEPINES AND NEW BENZODIAZEPINES OBTAINABLE THEREBY
Netherlands	7500364
France	1497456	Ortho-amino aryl cétimines, composés hétérocycliques qui s'y rattachent et prépaation de ces divers corps
Denmark	125856
Yugoslavia	32996
Yugoslavia	100565
Netherlands	155828

Market Dynamics and Financial Trajectory for Tranxene SD

Last updated: December 30, 2025

Executive Summary

Tranxene SD (Clorazepate Dipotassium Extended-Release), an FDA-approved medication for anxiety and seizure disorders, holds a niche yet strategically significant position within the anxiolytic pharmaceuticals landscape. Its market trajectory is influenced by evolving prescribing patterns, regulatory environments, competitive dynamics, and innovation trends. This analysis explores the current market landscape, growth drivers, risks, and future potential for Tranxene SD, providing essential insights for stakeholders assessing investment, development, or competitive positioning.

---

What is Tranxene SD?

Product Overview

• Generic Name: Clorazepate Dipotassium (Extended-Release)
• Indications: Anxiety disorders, epilepsy, and alcohol withdrawal
• Formulation: Extended-release oral tablets, typically 15 mg, 30 mg, and 45 mg strengths
• Mechanism of Action: Benzodiazepine receptor agonist enhancing GABA activity

Regulatory Status

• Approved by the U.S. Food and Drug Administration (FDA)
• Marketed mainly as a generic drug, with limited branded competition

---

Market Landscape and Competitive Positioning

Global and U.S. Market Size

Metric	2022 Estimates	2027 Projections	CAGR (2022-2027)	Source
Global anxiolytics market	USD 11.8 billion	USD 15.2 billion	5.4%	[1]
U.S. benzodiazepines segment	USD 3.2 billion	USD 3.9 billion	4.8%	[2]

Note: Tranxene SD is a small but steady contributor within this segment.

Market Drivers

• Rising prevalence of anxiety, estimated at 19% of adults in the U.S. annually ([3])
• Increasing prescribing of benzodiazepines for short-term management
• Growing awareness and treatment of epilepsy
• Expansion into niche markets like alcohol withdrawal management

Key Competition

Competitors	Strengths	Weaknesses	Market Share %	Notes
Xanax (alprazolam)	Dominant market presence	High abuse potential	~50%	Leading benzodiazepine in the U.S.
Valium (diazepam)	Long-established	Higher dependence risk	~20%	Widely prescribed, older drug
Ativan (lorazepam)	Fast-acting	Shorter half-life	~15%	Common in hospitals
Generic Clorazepate	Cost-effective	Limited brand recognition	N/A	Niche player

Tranxene SD’s extended-release formulation offers advantages in compliance and reduced dosing frequency.

---

Financial Trajectory Analysis

Revenue Trends

Tranxene SD’s direct revenue is primarily generated through generic sales. Due to its niche application and limited marketing, revenue estimates remain modest but stable.

Year	Estimated Revenue (USD millions)	Growth Rate	Notes
2018	20	—	Baseline year
2019	22	+10%	Steady growth
2020	23	+4.5%	Slight increase
2021	24	+4.3%	Market stabilization
2022	25	+4.2%	Mature market plateau

Profitability and Cost Dynamics

• Manufacturing costs: Relatively low due to established synthesis processes
• Pricing pressures: Increasing competition and patent expirations have driven prices downward
• Market share: Stabilized, with limited scope for significant expansion unless differentiated via formulations or indications

Regulatory and Market Entry Barriers

• Strict FDA regulatory path for generics
• Patent expirations and patent-litigation dynamics influence entry timelines
• Regulatory constraints around benzodiazepine scheduling and abuse potential impacts market access

---

Market Dynamics Influencing Future Growth

Prescribing Trends and Clinical Guidelines

• Shift towards non-benzodiazepine therapies for anxiety (e.g., SSRIs, SNRIs)
• Concerns over dependence and abuse potential lead to cautious prescribing and eventual tapering
• FDA warnings and REMS programs restrict off-label or long-term use

Regulatory and Policy Factors

• Potential scheduling re-evaluation of benzodiazepines may impact prescribing and sales
• Generic drug pricing policies and negotiations (Medicare, Medicaid) could pressure margins

Innovation and Product Differentiation

• Development of extended-release formulations aims for improved patient adherence
• Investigating combination therapies or novel delivery mechanisms to revitalize interest

---

SWOT Analysis of Tranxene SD Market Trajectory

Strengths	Weaknesses	Opportunities	Threats
Long-standing FDA approval	Limited brand recognition	Growing backlog of anxiety treatments	Intensifying competition
Niche in epilepsy and alcohol withdrawal	Generic status limits marketing	Potential formulations targeting unmet needs	Regulatory restrictions on benzodiazepines
Cost-effective manufacturing	Dependence on prescribing patterns	Strategic partnerships with healthcare providers	Rising safety concerns and shifts away from benzodiazepines

---

Key Market Drivers and Risks

Drivers	Risks
Increasing global and domestic demand	Regulatory crackdowns and scheduling restrictions
Expansion into niche indications	Market saturation and price competition
Adoption of extended-release formulations	Shift towards non-benzodiazepine therapies
Growing awareness of dependence issues	Development of safer alternatives

---

Comparison with Industry Benchmarks

Parameter	Tranxene SD	Industry Average	Remarks
Market Share	Small niche	Moderate (10-20%)	Limited due to competition from newer drugs
CAGR (2022-2027)	~3-4%	4-6%	Slightly below due to competitive pressures
Revenue Stability	Stable	Varies	Stable owing to long approval history
Innovation Pipeline	Minimal	Active	Limited innovation; focus on extension formulations

---

Future Outlook and Strategic Recommendations

Forecast Outlook (2023-2028)

• Market share: Expected to remain stable unless novel formulations or indications emerge
• Revenue growth: Likely to be slow (~2-3% annually) given generic market trends
• Regulatory landscape: Increased scrutiny could temper growth

Strategic Moves for Stakeholders

1. Invest in formulation improvements, such as once-daily dosing, to bolster adherence and differentiate.
2. Target niche indications, like alcohol withdrawal or specific epilepsy subtypes, to expand market share.
3. Engage with policymakers to navigate regulatory changes effectively.
4. Explore strategic partnerships with pharmacies or healthcare providers to enhance reach.
5. Monitor emerging therapies in the anxiolytics space, especially non-benzodiazepine options.

---

Key Takeaways

• Tranxene SD holds a niche but stable position in the anxiolytics and anticonvulsants markets, with moderate revenue and slow growth dynamics.
• Market growth is primarily driven by rising anxiety and epilepsy prevalence but tempered by regulatory pressures and evolving prescribing practices.
• Competition from branded benzodiazepines and newer therapeutics poses significant threats, especially as concerns over dependence limit long-term use.
• Innovation opportunities lie in improving formulations and expanding indications, although market entry remains challenging due to regulatory hurdles.
• Long-term prospects depend heavily on market shifts away from benzodiazepines, regulatory environments, and the ability to differentiate through formulation and indication expansion.

---

FAQs

1. What factors influence the future demand for Tranxene SD?
Demand hinges on benzodiazepine prescribing patterns, regulatory changes, the prevalence of anxiety and seizure disorders, and the development of alternative therapies. Regulatory restrictions and safety concerns may constrain growth, while an aging population with chronic conditions could sustain steady demand.

2. How does Tranxene SD compare to other benzodiazepines in terms of safety and efficacy?
Tranxene SD's extended-release formulation offers improved adherence and potentially reduced abuse liability compared to immediate-release benzodiazepines. However, safety profiles remain similar, with dependency and sedation risks common across the class.

3. What commercial strategies could enhance Tranxene SD’s market presence?
Focusing on niche indications, developing novel delivery systems, establishing clinical evidence for expanded use, and forming strategic partnerships can help sustain relevance. Pricing strategies and engaging with payers also influence market penetration.

4. Will regulatory changes threaten the longevity of Tranxene SD?
Yes. Increasing regulatory scrutiny over benzodiazepines due to dependence and abuse potential may restrict prescribing or lead to scheduling reclassification, which could diminish market access and sales.

5. What are the key innovation trends impacting Tranxene SD’s market?
Emerging trends include non-benzodiazepine anxiolytics (like SSRIs), digital health integrations for monitoring, and novel delivery modes—such as transdermal patches—that could threaten traditional formulations' market share.

---

References

1. Grand View Research, "Anxiolytics Market Size, Share & Trends Analysis," 2022.
2. IQVIA, "U.S. Benzodiazepine Market Report," 2022.
3. National Institute of Mental Health, "Mental Health Statistics," 2022.
4. FDA, "Benzodiazepine Drugs—Regulation and Safety," 2021.
5. MarketWatch, "Pharmaceutical Industry Trends," 2022.

---